Valuation: Avicanna Inc.

Market Cap 13.77M 9.66M 8.58M 8.03M 7.32M 930M 13.96M 97.11M 37.59M 474M 36.28M 35.5M 1.52B P/E 2024
-8.43x
P/E 2025 -9.36x
Enterprise Value 13.49M 9.47M 8.41M 7.86M 7.17M 912M 13.68M 95.13M 36.83M 464M 35.55M 34.77M 1.49B EV / Sales 2024
1.31x
EV / Sales 2025 1.03x
Free-Float
78.71%
Yield 2024 *
-
Yield 2025 -
1 day-9.26%
1 week-5.10%
Current month-9.30%
1 month-22.26%
3 months-31.51%
6 months-31.11%
Current year-56.69%
1 week 0.07
Extreme 0.0697
0.08
1 month 0.07
Extreme 0.0697
0.09
Current year 0.07
Extreme 0.06842
0.18
1 year 0.07
Extreme 0.06842
0.22
3 years 0.07
Extreme 0.06842
0.53
5 years 0.07
Extreme 0.06842
0.76
10 years 0
Extreme 0
3.53
Manager TitleAgeSince
Sales & Marketing - 01/05/2015
Chief Executive Officer 39 26/11/2016
Director of Finance/CFO - 15/09/2025
Director TitleAgeSince
Chairman 39 26/11/2016
Director/Board Member - 22/10/2018
Director/Board Member - 01/01/2026
Change 5-day change 1-year change 3-year change Capi.($)
-9.26%-5.10% - - 10.19M
+4.16%+3.04%+49.37%+94.17% 74.46B
-0.61%+0.81%+27.25%+82.72% 60.14B
-2.54%-1.65%+4.86%+31.72% 48.15B
-3.02%-5.20%+27.94%+32.51% 44.25B
+0.31%+3.02%+348.95%+643.82% 43.99B
-1.96%-0.33%+7.04%+99.46% 41.61B
+3.32%+3.49%+10.10%+51.23% 29.97B
+4.77%+8.00%+36.77%+22.78% 29.31B
-4.86%-10.66%-26.27%+330.06% 24.93B
Average -0.97%-0.08%+54.00%+154.28% 44.09B
Weighted average by Cap. +0.17%+0.11%+58.36%+145.78%

Financials

2024 2025
Net sales 25.46M 17.87M 15.87M 14.84M 13.52M 1.72B 25.81M 180M 69.5M 876M 67.08M 65.62M 2.81B 25.48M 17.88M 15.88M 14.85M 13.53M 1.72B 25.83M 180M 69.55M 877M 67.13M 65.67M 2.82B
Net income -3.62M -2.54M -2.25M -2.11M -1.92M -244M -3.67M -25.51M -9.88M -124M -9.53M -9.32M -400M -2.76M -1.94M -1.72M -1.61M -1.47M -186M -2.8M -19.46M -7.53M -94.94M -7.27M -7.11M -305M
Net Debt -339K -238K -211K -197K -180K -22.89M -343K -2.39M -925K -11.66M -893K -873K -37.44M -281K -197K -175K -164K -149K -18.96M -284K -1.98M -766K -9.66M -739K -723K -31.02M
Logo Avicanna Inc.
Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.
Employees
112
Date Price Change Volume
01/10/26 USD 0.0702 -9.26% 520,335
30/09/26 USD 0.0774 +1.84% 300
29/09/26 USD 0.0760 -2.69% 31,350
28/09/26 USD 0.0781 +5.11% 700
25/09/26 USD 0.0743 +0.44% 800